Uniquely formulated with a “maltol shield”

ACCRUFeR is a stable complex of ferric iron (Fe3+) and maltol, a naturally occurring sugar derivative.2 Unlike iron salts, this iron-sugar derivative complex stays intact in the stomach, dissociating when it reaches the duodenum for optimal iron absorption.2

The ACCRUFeR Mechanism of Action2-4

Iron is tightly bound within the maltol shield in the stomach.

The "maltol shield" protects iron from the stomach, remaining tightly bound as it passes through.

Dissociates upon uptake in the duodenum

Iron remains bioavailable, chelated, and ready to replenish iron stores. Excess iron is excreted in the stool.

Why the "maltol shield" matters:3,4,6

  • It allows iron in ACCRUFeR to remain bioavailable until it reaches the duodenum, where it can be efficiently absorbed. 

  • It reduces the likelihood of reactive oxygen species (ROS) formation, minimizing the risk for GI side effects and irritation or damage to the intestinal lining.

  • Since the iron and maltol remain chelated until absorption, there is less free iron in the gut, lessening the risk for added bowel inflammation.

Intolerable GI side effects can be a barrier to staying on oral iron replacement therapy.

Why ACCRUFeR?

ACCRUFeR pill bottle
For adults with ID/IDA2
ACCRUFeR is an FDA approved oral iron treatment for adults with iron deficiency.
Maltol shield
Shielded with maltol
Uniquely formulated with a "maltol shield" that keeps iron intact as it passes through the stomach, reducing the likelihood of reactive oxygen species formation, which in turn minimizes the GI side effects.2,4,6
RX document
Safety and efficacy
ACCRUFeR achieved FDA approval based on three pivotal studies in patients with ID/IDA associated with chronic inflammation and malabsorption.* Significant improvement across iron indices, including hemoglobin, ferritin, and TSAT.5,6

*Avoid use in patients with IBD flare.2

Person reaching up towards sun
Unprecedented tolerability
In clinical studies, 4.6% of patients taking ACCRUFeR (n=175) discontinued treatment due to adverse gastrointestinal reactions, compared with 2.5% of patients taking a placebo (n=120).2,5,6

ACCRUFeR's unprecedented tolerability

A 97% median overall treatment compliance was seen during the 12-week randomized period and during the 52- week open label extension.1

Established Safety and Efficacy
ACCRUFeR is backed by a robust clinical profile. It has demonstrated both short- and long-term efficacy across three pivotal clinical studies.
Downsides of Oral Iron Salts
GI side effects are a barrier to staying on traditional oral iron treatments.29
References:

1. Schmidt C, Ahmad T, Tulassay Z, et al. Ferric maltol therapy for iron deficiency anaemia in patients with inflammatory bowel disease: long-term extension data from a phase 3 study. Aliment Pharmacol Ther. 2016;44(3):259-270. doi:10.1111/apt.13665
2. ACCRUFeR® full prescribing information. Shield Therapeutics, 2023.
3. Stallmach A, Büning C. Ferric maltol (ST10): a novel oral iron supplement for the treatment of iron deficiency anemia in inflammatory bowel disease. Expert Opin Pharmacother. 2015;16:2859-2867.
4. European Medicines Agency. Accessed March 17, 2021. https://www.ema.europa.eu/en/documents/variation-report/feraccru-h-c-2733-ii-0010-epar-assessment-report-variation_en.pdf
5. Gasche C, Ahmad T, Tulassay Z, et al. Ferric maltol is effective in correcting iron deficiency anemia in patients with inflammatory bowel disease: results from a phase-3 clinical trial program. Inflamm Bowel Dis. 2015;21(3):579-588. doi:10.1097/mib.0000000000000314
6. Pergola PE, Kopyt NP. Oral ferric maltol for the treatment of iron-deficiency anemia in patients with CKD: a randomized trial and open-label extension. Am J Kidney Dis. 2021;78(6):846-856.e1. doi:10.1053/j.ajkd.2021.03.020
7. Data on file. Shield Therapeutics Inc. 2019
29. Lindgren S, Wikman O, Befrits R, et al. Intravenous iron sucrose is superior to oral iron sulphate for correcting anaemia and restoring iron stores in IBD patients: a randomized, controlled, evaluator-blind, multicentre study. Scand J Gastroenterol. 2009;44(7):838-845. doi:10.1080/00365520902839667